{
  "ticker": "AYA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958544",
  "id": "02958544",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250616",
  "time": "0848",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krxt0j8lx0cn.pdf",
  "summary": "### Material Information Summary:\n- **FDA 510(k) Submission**: Artrya submitted a pre-market application for its **Salix\u00ae Coronary Plaque module** (AI-powered plaque detection for coronary artery disease).  \n- **Expected FDA Clearance**: Q3 2025.  \n- **Commercial Integration**: Module integrates with previously cleared **Salix\u00ae Coronary Anatomy platform** (FDA-approved March 2025).  \n- **Reimbursement**: Qualifies under **U.S. CPT code** with **$950 per assessment** (Category I effective Jan 2026).  \n- **U.S. Partnerships**: Agreements with **3 hospital systems** (15 hospitals total) for rollout post-clearance.  \n- **Study Pipeline**: **SAPPHIRE study** underway to validate plaque risk scoring with potential commercial expansion.  \n\n*No capital raising, financials, or trading halt details identified.*",
  "usage": {
    "prompt_tokens": 2003,
    "completion_tokens": 186,
    "total_tokens": 2189,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T22:59:50.702737"
}